Bajaj Healthcare Reports Q2 & H1 FY26 Results with Strong Margin Expansion

Bajaj Healthcare Limited, a leading manufacturer of APIs, Intermediates and Formulations, announced its un-audited financial results for the quarter and half year ended 30th September 2025. The company reported a Y-o-Y revenue growth of 11% and a 49% Y-o-Y growth in profit from continuing operations. The gross margin expanded by 462 basis points to 50.8%, while EBITDA margin improved by 217 basis points to 19.1%. The company also reported a 67% Y-o-Y growth in exports and is focusing on high-margin products for long-term margin stability. Bajaj Healthcare has also strengthened its regulatory compliance and global presence, with a focus on expanding in regulated markets and aligning its pipeline with high-value therapeutic areas.